RT Journal Article
SR Electronic
T1 Secondary Analyses for Genome-wide Association Studies using Expression Quantitative Trait Loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.20.21260862
DO 10.1101/2021.07.20.21260862
A1 Ngwa, Julius S
A1 Yanek, Lisa R
A1 Kammers, Kai
A1 Kanchan, Kanika
A1 Taub, Margaret A
A1 Scharpf, Robert B
A1 Faraday, Nauder
A1 Becker, Lewis C
A1 Mathias, Rasika A
A1 Ruczinski, Ingo
YR 2021
UL http://medrxiv.org/content/early/2021/07/22/2021.07.20.21260862.abstract
AB Genome-wide association studies (GWAS) have successfully identified thousands of single nucleotide polymorphisms (SNPs) associated with complex traits; however, the identified SNPs account for a fraction of trait heritability, and identifying the functional elements through which genetic variants exert their effects remains a challenge. Recent evidence suggests that SNPs associated with complex traits are more likely to be expression quantitative trait loci (eQTL). Thus, incorporating eQTL information can potentially improve power to detect causal variants missed by traditional GWAS approaches. Using genomic, transcriptomic, and platelet phenotype data from the Genetic Study of Atherosclerosis Risk family-based study, we investigated the potential to detect novel genomic risk loci by incorporating information from eQTL in the relevant target tissues (i.e. platelets and megakaryocytes). Permutation analyses were performed to obtain family-wise error rates for eQTL associations, substantially lowering the genome-wide significance threshold for SNP-phenotype associations. In addition to confirming the well known association between PEAR1 and platelet aggregation, our eQTL focused approach identified a novel locus (rs1354034) and gene (ARHGEF3) not previously identified in a GWAS of platelet aggregation phenotypes. A colocalization analysis showed strong evidence for a functional role of this eQTL.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for methodological work was provided through NIH NHLBI R01 HL141944 (Rasika Mathias and Ingo Ruczinski, co-PIs). GeneSTAR was supported through NIH NHLBI U01s HL072518, HL087698, HL112064, and M01-RR000052 to the Johns Hopkins General Clinical Research Center from the NIH National Center for Research Resources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins Medicine IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available in the database of Genotypes and Phenotypes (dbGaP, www.ncbi.nlm.nih.gov/gap/) under accession number phs001218.v2.p1. https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001218.v2.p1